Carlos Cruchaga

Additional Titles & Roles

---

• Professor of Neurology
• Professor of Genetics
• Professor of Genetics
• Professor of Neurology
• Knight-ADRC Genetics and Hight-throughput Omics Core leader
• DIAN (The Dominantly Inherited Alzheimer Network) Genetics Core co-leader
• Scientific advisor McDonnell Genome Institute (MGI)
• Director NeuroGenomics and Informatics lab

Education & Training

---

• Ph.D.: University of Navarra, 2005
• M.S.: University of Navarra, 2002
• B.S.: University of Navarra, 2000

View clinician profile

Research Interests

---

Dr. Cruchaga is a human genomicist with expertise in multiomics, informatics, and neurodegeneration. He completed his PhD in Biochemistry and Molecular Biology in 2005 at the University of Navarra in Spain. During his first postdoc with Dr. Pastor he conducted statistical human genetics studies focused on Alzheimer’s disease (AD) and Parkinson’s disease (PD). He then moved to Dr. Goate’s Lab to complete his training in quantitative human genomics. Dr. Cruchaga established his laboratory at Washington University in 2011 to study the genetic architecture of neurodegenerative diseases. His interests are focused on using human genomic and other -omic data (proteomics, metabolomics, and lipidomics) to identify and understand the biological processes that lead to AD, PD, frontotemporal dementia, and other neurodegenerative processes. He is the founding director of the NeuroGenomics and Informatics Center at Washington University.

Visit lab website

Recent Publications

---

• CSF Glucose-6-Phosphate Isomerase Is a Tau-Related Biomarker Associated with Neurodegeneration and Cognitive Impairment in Alzheimer’s Disease

  Alzheimer’s Disease Neuroimaging Initiative, Jan 2026, In: Molecular Neurobiology. 63, 1, 47.

• Proteomic polygenic risk scores of age-related plasma protein levels reveal a role for Metalloproteinase inhibitor 2 (TIMP2) in cognitive performance

  Anastasi, F., Genius, P., Rodriguez-Fernandez, B., Yang, C., Gorijala, P., Timsina, J., Hernández-Villamizar, F., Lorenzini, L., del Campo, M., Sánchez-Benavides, G., Minguillon, C., Navarro, A., Cruchaga, C., Suárez-Calvet, M. & Vilor-Tejedor, N., Jan 2026, In: Neurobiology of Aging. 157, p. 68-78 11 p.

• Domain mapping of disease mutations reveals pathogenic SORL1 variants in Alzheimer’s disease

  Andersen, O. M., de Waal, M. W. J., Monti, G., Tesi, N., Jensen, A. M. G., de Geus, C., van Spaendonk, R., Vogel, M., Ahmad, S., Amin, N., Amouyel, P., Beecham, G. W., Bellenguez, C., Berr, C., Bis, J. C., Boland, A., Bossù, P., Bouwman, F., Bras, J. & Charbonnier, C. & 86 others, Clarimon, J., Cruchaga, C., Daniele, A., Dartigues, J. F., Debette, S., Deleuze, J. F., Denning, N., DeStefano, A. L., Dols-Icardo, O., van Duijn, C. M., Farrer, L. A., Fernandez Hernandez, V., van der Flier, W. M., Fox, N. C., Galimberti, D., Genin, E., Gille, J. J. P., Grenier-Boley, B., Grozeva, D., Guen, Y. L., Guerreiro, R., Haines, J. L., Holmes, C., Hummerich, H., Arfan Ikram, M., Kamran Ikram, M., Kawalia, A., Kraaij, R., Lambert, J. C., Lathrop, M., Lemstra, A. W., Lleó, A., Myers, R. M., Mannens, M. M. A. M., Marshall, R., Martin, E. R., Masullo, C., Mayeux, R., Mead, S., Mecocci, P., Meggy, A., Mol, M. O., Nacmias, B., Naj, A. C., Napolioni, V., Nicholas Cochran, J., Nicolas, G., Pasquier, F., Pastor, P., Pericak-Vance, M. A., Pijnenburg, Y. A. L., Piras, F., Quenez, O., Ramirez, A., Raybould, R., Redon, R., Reinders, M. J. T., Richard, A. C., Riedel-Heller, S. G., Rivadeneira, F., van Rooij, J. G. J., Rousseau, S., Ryan, N. S., Sanchez-Juan, P., Schellenberg, G. D., Scheltens, P., Schott, J. M., Seshadri, S., Sie, D., Sims, R., Sistermans, E. A., Sorbi, S., van Swieten, J. C., Tijms, B., Uitterlinden, A. G., Visser, P. J., Wagner, M., Wallon, D., Wang, L. S., Williams, J., Yokoyama, J. S., Zarea, A., van der Lee, S. J., Olsen, J. G., Hulsman, M. & Holstege, H., Dec 2025, In: Molecular neurodegeneration. 20, 1, 122.

• Proteogenomics in cerebrospinal fluid and plasma reveals new biological fingerprint of cerebral small vessel disease

  Caro, I., Western, D., Namba, S., Sun, N., Kawaguchi, S., He, Y., Fujita, M., Roshchupkin, G., D’Aoust, T., Duperron, M. G., Sargurupremraj, M., Tsuchida, A., Koido, M., Ahmadi, M., Yang, C., Timsina, J., Ibanez, L., Matsuda, K., Suzuki, Y. & Oda, Y. & 37 others, Kanai, A., Jandaghi, P., Munter, M., Auld, D., Astafeva, I., Puerta, R., Rotter, J. I., Psaty, B. M., Bis, J. C., Longstreth, W. T., Couffinhal, T., García-González, P., Pytel, V., Marquié, M., Cano, A., Boada, M., Joliot, M., Lathrop, M., Le Grand, Q., Launer, L. J., Wardlaw, J. M., Heiman, M., Ruiz, A., Matthews, P. M., Seshadri, S., Fornage, M., Adams, H., Mishra, A., Trégouët, D. A., Okada, Y., Kellis, M., De Jager, P. L., Tzourio, C., Kamatani, Y., Matsuda, F., Cruchaga, C. & Debette, S., Dec 2025, In: Nature Aging. 5, 12, p. 2514-2531 18 p.

• TMEM175, SCARB2 and CTSB associations with Parkinson’s disease risk across populations

  the Global Parkinson’s Genetic Program (GP2), Dec 2025, In: npj Parkinson’s Disease. 11, 1, 348.

See more publications

See NCBI publications

Funded Research Projects

---

View NIH Research